Englebienne P, Doyen G
J Steroid Biochem. 1983 Jun;18(6):649-53. doi: 10.1016/0022-4731(83)90242-x.
We further studied the androgen-binding protein (ABP) that we recently evidenced in the serum from two patients with hydatidiform mole [Ref. 4]. This protein was further shown to be distinct from the sex hormone-binding globulin (SHBG) by concanavalin A and ion-exchange chromatographies, as well as spectrophotometric and kinetic studies. However, the ABP was shown to have a molecular weight and relative affinities for several steroids, similar to those of SHBG. Our results lead us to suppose that the ABP previously evidenced in molar vesicles and fluid [Ref. 5] is secreted in the serum. It is, however, likely that the secretion process alters the binding affinity of this protein. The presence of this additional binding component in the serum of patients with such trophoblastic tumours, may reduce severely the free 17 beta-hydroxyandrogens levels, as well as may help create a release gradient in the serum steroids buffer stores.
我们进一步研究了雄激素结合蛋白（ABP），我们最近在两名葡萄胎患者的血清中发现了这种蛋白[参考文献4]。通过伴刀豆球蛋白A和离子交换色谱法以及分光光度法和动力学研究，进一步证明这种蛋白与性激素结合球蛋白（SHBG）不同。然而，ABP的分子量和对几种类固醇的相对亲和力与SHBG相似。我们的结果使我们推测，先前在葡萄胎水泡和液体中发现的ABP是分泌到血清中的。然而，分泌过程可能会改变这种蛋白的结合亲和力。这种滋养层肿瘤患者血清中这种额外结合成分的存在，可能会严重降低游离17β-羟基雄激素水平，也可能有助于在血清类固醇缓冲储存中形成释放梯度。
